Brookfield 02 April 2009Honeywell HomMed has received approval for its Genesis DM telehealth monitor from the Therapeutic Goods Administration (TGA), Australia's regulatory agency for medical drugs and devices. Honeywell HomMed's telehealth solution enables patients to take a more active role in their health, improving the quality of patient care, increasing economic benefits for health care systems and providing patients with greater independence.

Advertisement

"The approval is an important step for us as we expand our international footprint to deliver the industry leading Genesis DM telehealth monitor and LifeStream Telehealth Ecosystem to the Australian health care market", stated Terry Duesterhoeft, president of Honeywell HomMed.

Patients with chronic conditions such as congestive heart failure and chronic obstructive pulmonary disease use the Genesis DM telehealth monitor, a Gold winner of the 2008 Medical Design Excellence Awards (MDEA), from the comfort of their own homes to monitor vital signs such as blood pressure, heart rate and oxygen levels on a daily basis. The information is immediately transmitted to health care professionals, allowing them to quickly react to any changes or problems in patients' health.

Honeywell HomMed's Genesis DM telehealth monitors and LifeStream remote patient care system have been selected for the Telehealth Lifestyle Co-ordination (TLC) Project in Ipswich, Australia. A selected group of community members with chronic conditions will participate in the 18-month clinical trial, which is supported by local community group Ipswich Community Aid and Tunstall Healthcare. The trial will focus on four patient groups: cardiac, respiratory, endocrine and individuals with other conditions.

"We are excited to work with one of the fastest growing telehealth regions in the world and to provide a comprehensive, standardized solution to the TLC Project", Terry Duesterhoeft stated. "The project offers a great opportunity to demonstrate the benefits and suitability of telehealth for Australian patients and the Australian health care system."

Honeywell International is a $37 billion diversified technology and manufacturing expert, serving customers worldwide with aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Based in Morris Township, New Jersey, Honeywell's shares are traded on the New York, London and Chicago Stock Exchanges.